Drugs / VRVg 1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03145766 | Apr 2017 → Jan 2018 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRVg 1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03145766 ↗ |
| Route | Intramuscular | “VRVg-1 initial formulation, IM injection on Days 0, 3, 7, 14 and 28.” NCT03145766 ↗ |